T H E R A P E U T I C S
  • About Us
  • Our Science
  • Pipeline
    • ENX-101
    • ENX-102
    • ENX-103
    • ENX-104
    • ENX-105
  • Investors & Media
  • Partners
  • Careers
  • Contact Us
Menu
  • About Us
  • Our Science
  • Pipeline
    • ENX-101
    • ENX-102
    • ENX-103
    • ENX-104
    • ENX-105
  • Investors & Media
  • Partners
  • Careers
  • Contact Us

About Us

Engrail Therapeutics is a clinical-stage pharmaceutical company founded in 2019 with the aspiration of becoming a leader in neuroscience. We are committed to rapidly advancing our innovative, precision-targeted therapeutics.

Our purpose is to deliver transformational therapies that improve the lives of patients with devastating neurologic, neuropsychiatric, and neurodevelopmental disorders.

LEADERSHIP TEAM

Vikram Sudarsan, PhD

President and Chief Executive Officer

Kimberly Vanover, PhD

Chief Scientific Officer

Eve Taylor, PhD

Sr. VP, Clinical Development

Camilla Gomiero

VP, Commercial Strategy & Business Development

Neil Mhaskar, PhD

VP, Drug Development & Manufacturing

Rex E. Bosen, CPA

Acting Chief Financial Officer

Estibaliz Arce, PhD

VP, Translational Science & Clinical Development

Anil Vootkur, PharmD

VP, Corporate Development

Bill Brubaker, PhD

Sr. VP, Nonclinical Development

BOARD OF DIRECTORS

Peter Bisgaard

Chairman of the Board
Managing Director, Pivotal Life Sciences

Vikram Sudarsan, PhD

Board Member
President and Chief Executive Officer, Engrail Therapeutics

Kimberly Vanover, PhD

Board Member
Chief Scientific Officer, Engrail Therapeutics

Karoly Nikolich, PhD

Board Member
Venture Partner, Pivotal Life Sciences

Tony Ho, MD, PhD

Independent Board Member
Former EVP R&D, CRISPR Therapeutics

T H E R A P E U T I C S

© 2022 Engrail Therapeutics. All rights reserved.

  • ABOUT US
  • OUR SCIENCE
  • PIPELINE
  • INVESTORS & MEDIA
  • PARTNERS
  • CAREERS
  • CONTACT US
  • Legal disclaimer
  • Privacy policy
  • Terms of use
COOKIES
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Accept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT

Vikram Sudarsan, PhD

President and Chief Executive Officer

Vikram is a neuroscientist, investor, entrepreneur, and industry veteran with nearly 25 years of industry experience. Most recently, Vikram was CEO of Cipla Technologies and built a pipeline of branded products to treat CNS disorders and respiratory diseases. Prior to that, Vikram was head of Strategy for Cipla New Ventures. Vikram’s career experience spans a wide spectrum of industry functions, including venture capital, business development, transactions, market access, drug idea generation, drug development, and operations. Vikram served on the boards of Stempeutics, Chase Pharmaceuticals, Cipla Technologies, and Cipla USA. Vikram received his PhD from the University of Sheffield and completed his post-doctorate at Stanford University School of Medicine.

Kimberly Vanover, PhD

Chief Scientific Officer

Kimberly is a highly accomplished neuropsychiatric and neurodegenerative drug discoverer and developer with over 25 years of industry experience. Most recently, Kimberly served as SVP, Clinical Development and SVP, Early-Stage Clinical Development and Translational Medicine at Intra-Cellular Therapies, guiding Caplyta (lumateperone) from early development to approval. Prior to Intra-Cellular, Kimberly worked at Acadia Pharmaceuticals, playing a key role in the development of Nuplazid (pimavanserin). Kimberly received her PhD in Biopsychology from the University of Chicago and completed her postdoctoral training at the University of California – San Diego and Lederle Laboratories.

Eve Taylor, PhD

Sr. VP, Clinical Development

Eve has over 20 years of industry experience with a specific focus on neuroscience clinical development and operations. Most recently, Eve helped lead early-stage clinical development at Intra-Cellular Therapies. Previously, Eve led clinical development activities at Cytori Therapeutics, Ceregene, and Acadia Pharmaceuticals. Eve has also served as founder and lead at Taylored BioConsulting, providing clinical development and other consulting services. Eve received her BSc (Hons) from the University of Western Australia, PhD in Biochemistry from King’s College London, and completed her postdoctoral training at the Salk Institute for Biological Studies and University of California – San Diego.

Camilla Gomiero

VP, Commercial Strategy & Business Development

Camilla has over 10 years of industry experience advising companies on commercial launch strategies, conducting early-stage asset valuations, and leading commercial due diligence as a consultant focused on the life sciences. Camilla has worked with key stakeholders within industry to identify and communicate the commercial potential for new treatments across multiple therapy areas and stages of development, with recent expertise in orphan drugs and neurosciences. Camilla previously held positions as Engagement Manager and Consultant with Two Labs, IMS Health and ICON. While at IMS, Camilla helped establish IMS Health Capital, an investment banking company.

Neil Mhaskar, PhD

VP, Drug Development & Manufacturing

Neil has over 30 years of experience in pharmaceutical development, CMC strategy, global technical operations, supply chain management, CMC regulatory affairs, and compliance from precandidate nomination through Phase 1 – Phase 3 clinical development to market launch and lifecycle management. Recently, Neil was VP of CMC at ORIC Pharmaceuticals and Prana Biotechnology, where he led critical development, strategic planning, and technical operations for drug substances, drug products, and CTMs in support of global clinical trials. Neil also served in senior CMC management roles with Takeda/Millennium, Sanofi Genzyme, and Gilead Sciences, where he made significant contributions to the development pipeline and marketed products such as Mozobil®, Zydelig®, Campath®, and Remdesivir®. Neil received his PhD in Chemistry from MS University, India, and completed his postdoctoral research at Rice University, Wiess School of Natural Sciences.

Rex E. Bosen, CPA

Acting Chief Financial Officer

Rex has over 30 years of experience in public and corporate accounting and finance. Rex’s corporate career includes a variety of progressive roles, including CFO at Hocking International Laboratories, LLC; SVP, Finance and Accounting at Provide Commerce, Inc., and Proflowers, Inc.; CFO and founder at PhatPipe, Inc., and Controller at EG Electro-Graph, Inc. Rex has direct experience in the preparation and successful placement of an IPO along with several corporate acquisition and sale transactions. Rex also had a successful tax and consulting practice as a sole practitioner. Rex received his Master of Accountancy from Brigham Young University.

Estibaliz Arce, PhD

VP, Translational Science & Clinical Development

Estibaliz Arce is a licensed clinical psychologist specializing in neurocognition and neuroimaging, with more than 20 years of experience in the academic and biotech/pharmaceutical sectors.

Esti completed her BSc and PhD in clinical psychology at Universidad de Deusto, Spain. She came to the United States to complete a clinical psychiatry internship at Crownsville State Hospital (MD) as well as her dissertation at USC (CA). Following the completion of her doctorate, she pursued postdoctoral fellowships at UCLA and UCSD, where she focused on clinical/neuropsychological evaluations and treatment for psychotic and affective disorders, as well as understanding the neural underpinnings of cognitive and emotional processes in several psychiatric populations using fMRI.

Following her academic training, Esti has held several clinical and translational research positions at Wyeth, EMD Serono, Pfizer, and Biogen, contributing to the development of treatments for multiple sclerosis, schizophrenia, and depression, among other CNS indications. 

Anil Vootkur, PharmD

VP, Corporate Development

Anil has over 20 years of industry experience with demonstrated success in corporate strategy, business development, global and regional in-line and upstream marketing, as well as medical affairs and communications. Prior to joining Engrail, Anil spent several years in corporate strategy as well as leading neurosciences global strategic marketing at Allergan. Prior to Allergan, Anil worked in a variety of progressive leadership positions across functions at Takeda, including commercial strategy and execution, business development, and medical strategy. Anil has also served as founder and principal of ARINA LifeSciencesConsulting. Anil received his Doctorate in Pharmacy from the University of Illinois – Chicago.

Bill Brubaker, PhD

Sr. VP, Nonclinical Development

Bill is a highly sought-after non-clinical development expert and entrepreneur with over 35 years of industry experience leading teams and diverse programs to successful outcomes.   As President of Farmington Pharma Development, a consulting service he founded in 2004, he has led dozens of clients’ programs from early-stage discovery through successful IND filings and beyond.  More recently, he served as Nayan Pharmaceutical’s Head of Non-clinical Development; Project Leader and MedChem Director for Ultragenyx Pharmaceutical‘s creatine transporter disorder program; and, as acting CEO, he led Bikam Pharmaceuticals to a successful acquisition by Shire.  Bill received his PhD in Chemistry from Virginia Tech and completed his postdoctoral training at Yale University School of Medicine.

Peter Bisgaard

Chairman of the Board

Managing Director, Pivotal Life Sciences

Peter Tuxen Bisgaard has served as the Chairman of our board of directors since June 2019. Since September 2017, Mr. Bisgaard has been Managing Director of Nan Fung Life Sciences, a global life sciences investment platform, and a Managing Partner at Pivotal Bioventure Partners LLC, a healthcare venture capital fund. Prior to this, he was a Senior Partner at Novo Ventures, a healthcare-focused venture investment firm, from 2009 to September 2017. Prior to Novo Ventures, he was with McKinsey and Co. He has previously served on the board of directors of the following publicly-held companies: Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company; Nevro Corp, a commercial-stage medical device company; HTG Molecular Diagnostics, Inc., a commercial-stage RNA-platform based life sciences tools company; Otonomy, Inc., a biopharmaceutical company developing therapeutics for treating hearing disorders; and Alder Biopharmaceuticals, Inc., a late-stage drug development company focusing on migraine therapeutics. In addition, Mr. Bisgaard is serving, and has served, on numerous boards of privately held biotechnology and medical technology companies. Mr. Bisgaard received an M.Sc. in engineering from the Technical University of Denmark and a post-graduate degree in mathematical modeling in economics from the European Consortium for Mathematics in the Industry.

Vikram Sudarsan, PhD

Board Member

President and Chief Executive Officer, Engrail Therapeutics

Vikram is a neuroscientist, investor, entrepreneur, and industry veteran with nearly 25 years of industry experience. Most recently, Vikram was CEO of Cipla Technologies and built a pipeline of branded products to treat CNS disorders and respiratory diseases. Prior to that, Vikram was head of Strategy for Cipla New Ventures. Vikram’s career experience spans a wide spectrum of industry functions, including venture capital, business development, transactions, market access, drug idea generation, drug development, and operations. Vikram served on the boards of Stempeutics, Chase Pharmaceuticals, Cipla Technologies, and Cipla USA. Vikram received his PhD from the University of Sheffield and completed his post-doctorate at Stanford University School of Medicine.

Kimberly Vanover, PhD

Board Member

Chief Scientific Officer, Engrail Therapeutics

Kimberly is a highly accomplished neuropsychiatric and neurodegenerative drug discoverer and developer with over 25 years of industry experience. Most recently, Kimberly served as SVP, Clinical Development and SVP, Early-Stage Clinical Development and Translational Medicine at Intra-Cellular Therapies, guiding Caplyta (lumateperone) from early development to approval. Prior to Intra-Cellular, Kimberly worked at Acadia Pharmaceuticals, playing a key role in the development of Nuplazid (pimavanserin). Kimberly received her PhD in Biopsychology from the University of Chicago and completed her postdoctoral training at the University of California – San Diego and Lederle Laboratories.

Karoly Nikolich, PhD

Board Member

Venture Partner, Pivotal Life Sciences

Karoly Nikolich is a member of the Board of Directors of Engrail Therapeutics. During the 1980s, he led Genentech’s entry into neuroscience and led and participated in the development of numerous protein therapeutics. He was Vice President of Research at Lynx Therapeutics, co-founder of AGY Therapeutics, Amnestix, Neurofluidics, Chase Pharmaceuticals, Circuit Therapeutics, and Alkahest. He has also served as a venture partner with Pivotal BioVentures and has been on the boards and scientific advisory boards of a number of neurotherapeutics and biotech companies. He currently serves as Chair on the Board of Directors at Alkahest, a Grifols company. He has been an Adjunct Professor in the Department of Psychiatry at Stanford University Medical School. Dr. Nikolich is a graduate of Eotvos University in Budapest and worked as a postdoctoral fellow at Tulane University and UCSF before joining Genentech.

Tony Ho, MD, PhD

Independent Board Member

Former EVP R&D, CRISPR Therapeutics

Dr. Tony Ho currently serves as a member of the Board of Directors at Engrail Therapeutics. Most recently, Dr. Ho served as Executive Vice President and Head of R&D at CRISPR Therapeutics. Tony was previously SVP and Head of Oncology Integration and Innovation at AstraZeneca. He oversaw both the development and commercialization of Lynparza and Imfinizi. Prior to joining AstraZeneca, Tony was the Neurology and Ophthalmology Clinical Section Head at Merck and led multiple development programs, including the approval of Maxalt for pediatric migraine and Zioptan for glaucoma. Prior to joining Merck, Tony was the Co-Founder and CSO of Neuronyx, a regenerative medicine company. Tony received a BS from UCLA and an MD from Johns Hopkins University. He was Assistant Neurology Professor at Hopkins. Tony described and elucidated the pathogenesis of acute motor axonal neuropathy (AMAN). He has published widely with over 80 papers and is a co-inventor of 14 patents. Tony is currently an adjunct Associate Professor of Neurology at the University of Pennsylvania and Assistant Professor (Part-time) of Neurology at Johns Hopkins University.

Stephen Cunningham, MD, FRCP, FFPM

Board Member

EVP, Research & Development and Chief Development Officer, Engrail Therapeutics

Stephen is an experienced pharmaceutical executive with 30 years of expertise leading the development, approval, launch, and lifecycle management of blockbuster drugs across multiple therapeutic areas. Prior to cofounding Engrail Therapeutics, Stephen gained broad portfolio experience at Zeneca and AstraZeneca. After 12 years at Zeneca/AstraZeneca, he spent 13 years at Novartis in the US as CSO and head of clinical development and medical affairs. Most recently, Stephen served as a key advisor to Chase Pharmaceuticals, Cipla Technologies, and Pharmascience on the development of portfolios that led to high-value acquisitions. Stephen has extensive experience in the development of drugs in the neuroscience area and received his MD from Queen’s University Belfast.

Jordi Serrats, PhD

VP, Preclinical Development & Neurobiology

Jordi is a renowned neurobiologist with nearly 20 years of neuroscience research and industry experience. Most recently, Jordi led the neurodevelopmental disorders biotech unit of Takeda and was a major contributor to the design and progression of its novel drug discovery portfolio. Prior to his tenure at Takeda, Jordi made significant contributions to the neuroinflammation unit at Lundbeck. Jordi received his PhD from the University of Barcelona (focus on the serotonergic system) and completed his postdoctoral studies in neuroinflammation at the Salk Institute for Biological Studies under the mentorship of Dr. Paul Sawchenko.

Stephen Cunningham, MD, FRCP, FFPM

EVP, Research & Development and Chief Development Officer

Stephen is an experienced pharmaceutical executive with 30 years of expertise leading the development, approval, launch, and lifecycle management of blockbuster drugs across multiple therapeutic areas. Prior to cofounding Engrail Therapeutics, Stephen gained broad portfolio experience at Zeneca and AstraZeneca. After 12 years at Zeneca/AstraZeneca, he spent 13 years at Novartis in the US as CSO and head of clinical development and medical affairs. Most recently, Stephen served as a key advisor to Chase Pharmaceuticals, Cipla Technologies, and Pharmascience on the development of portfolios that led to high-value acquisitions. Stephen has extensive experience in the development of drugs in the neuroscience area and received his MD from Queen’s University Belfast.